Presentations From prIME Masterclass in Head & Neck Cancer
prIME Downloadable Slides
prIME Downloadable Slides

Presentations From prIME Masterclass in Head & Neck Cancer

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

Improve your understanding of head & neck (H&N) cancer with insights from the experts on the importance of a multidisciplinary team approach, the role of surgery and postoperative strategies, and nonsurgical treatment options, including immunotherapy, for patients with advanced/recurrent head & neck cancer.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jul 15, 2017

Expiration Date

Jul 15, 2018

Featured Expert

  • Athanassios Argiris, MD, PhD, FACP, Hygeia Hospital, Athens, Greece

Featured Topic

Keynote presentation—State-of-the-art management of H&N cancer in 2017: Current guidelines and unanswered questions

Featured Expert

  • Naomi Kiyota, MD, PhD, Kobe University Hospital, Kobe, Japan

Featured Topic

Multidisciplinary treatment approach: Role of multidisciplinary team

Featured Expert

  • Chih-Yen Chien, MD, FACS, Kaohsiung Chang Gung Memorial Hospital
    and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Featured Topic

Multidisciplinary treatment approach: Imaging and surgical approaches in locally advanced head and neck squamous cell carcinoma (HNSCC)

Featured Expert

  • Athanassios Argiris, MD, PhD, FACP, Hygeia Hospital, Athens, Greece

Featured Topic

Multidisciplinary treatment approach: Emerging postoperative treatment strategies

Featured Expert

  • James Bonner, MD, University of Alabama at Birmingham, Birmingham, Alabama, United States

Featured Topic

Nonsurgical treatment of locally advanced HNSCC: Managing locally advanced oropharyngeal cancer

Featured Expert

  • Jin-Ching Lin, MD, PhD, Taichung Veterans General Hospital , Taichung, Taiwan

Featured Topic

Nonsurgical treatment of locally advanced HNSCC: Strategies to reduce radiation-related toxicities in patients with HNSCC

Featured Expert

  • Naomi Kiyota, MD, PhD, Kobe University Hospital, Kobe, Japan

Featured Topic

Role of targeted therapy in H&N cancer in the era of immunotherapy

Featured Experts

  • Athanassios Argiris, MD, PhD, FACP, Hygeia Hospital, Athens, Greece
  • Chih-Yen Chien, MD, FACS, Kaohsiung Chang Gung Memorial Hospital
    and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Featured Topic

prIME Points™

This educational activity is specifically designed to meet the needs of oncologists, registered nurses, and other healthcare professionals involved in the treatment of patients with CRC.

After successful completion of this educational activity, participants should be able to:

  • Explain current state-of-the-art management of H&N cancer and the importance of a multidisciplinary team approach
  • Identify importance of appropriate imaging and role of surgery in locally advanced HNSCC
  • Select optimal therapy for individual patients with H&N cancer based on guideline recommendation and available evidence
  • Describe emerging postoperative treatment strategies
  • Assess nonsurgicaltreatment options for locally advanced H&N cancer and strategies to reduce radiation-induced toxicities
  • Evaluate the current and emerging role of targeted therapy and immunotherapy in advanced/recurrent HNSCC

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.